Form 10-Q · Quarterly report
Abbott Laboratories 10-Q, filed Jul 28, 2026
- Filed
- CIK
- 0000001800
- Accession no.
- 0001628280-26-050134
Summary
Abbott Laboratories reported second-quarter 2026 net sales of $12.59 billion, up 13.0% from a year earlier, as its March 23, 2026 acquisition of Exact Sciences for about $20.6 billion lifted Diagnostic Products sales 42.3% and offset a 3.1% decline in Nutritional Products. R&D expenses rose 22.9% to $892 million and SG&A rose 30.3% to $4.0 billion in the quarter, largely on the Exact Sciences addition and related integration costs.
Key points
- Second-quarter net sales rose 13.0% to $12.59 billion, or 12.2% excluding foreign exchange; first-half sales rose 10.5% to $23.76 billion, or 8.2% excluding foreign exchange.
- Abbott completed the acquisition of Exact Sciences on March 23, 2026 for approximately $20.6 billion, paying $105 per common share in cash and funding it mainly with $20.0 billion of long-term debt issued in March 2026.
- Diagnostic Products sales rose 22.4% excluding foreign exchange in the first half, including about $1.0 billion from Exact Sciences reported as Cancer Diagnostics, while Rapid and Molecular Diagnostics fell 8.8% on weaker respiratory virus testing demand.
- Nutritional Products sales fell 5.6% excluding foreign exchange in the first half, and in May 2026 Abbott secured CE Mark for Libre Duo, its dual glucose-ketone biowearable sensor.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations Financial Review — Results of Operations Abbott’s revenues are derived primarily from the sale of a broad portfolio of healthcare products under short-term receivable arrangements. Patent protection and licenses, technological and performance features, and inclusion of Abbott’s products under a contract most significantly impact which products are sold; price controls, competition, and rebates most significantly impact the net selling prices of products; and foreign currency translation impacts the measurement of net sales and costs. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.